Composition of fibrin glues significantly influences axial vascularization and degradation in isolation chamber model

Arkudas, Andreas; Pryymachuk, Galyna; Hoereth, Tobias; Beier, Justus P.; Polykandriotis, Elias; Bleiziffer, Oliver; Gulle, Heinz; Horch, Raymund E.; Kneser, Ulrich

doi:10.1097/mbc.0b013e3283540c0f

Cited by 17 publications

(9 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using an isolation chamber model of an arteriovenous loop, it was reported that levels of fibrinogen in fibrin sealant have a significant effect on the amount of matrix degradation and vascular in growth [110]. Lower levels of fibrinogen (20 mg/mL as compared to ≥80 mg/mL) appear to increase matrix degradation ( P < 0.05) and increase the amount of vascularized connective tissue ( P < 0.05) present.…”

Section: Fibrin Sealant Laboratory Literaturementioning

confidence: 99%

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

2014

View full text Add to dashboard Cite

Background. Fibrin sealant became the first modern era material approved as a hemostat in the United States in 1998. It is the only agent presently approved as a hemostat, sealant, and adhesive by the Food and Drug Administration (FDA). The product is now supplied as patches in addition to the original liquid formulations. Both laboratory and clinical uses of fibrin sealant continue to grow. The new literature on this material also continues to proliferate rapidly (approximately 200 papers/year). Methods. An overview of current fibrin sealant products and their approved uses and a comprehensive PubMed based review of the recent literature (February 2012, through March 2013) on the laboratory and clinical use of fibrin sealant are provided. Product information is organized into sections based on a classification system for commercially available materials. Publications are presented in sections based on both laboratory research and clinical topics are listed in order of decreasing frequency. Results. Fibrin sealant remains useful hemostat, sealant, and adhesive. New formulations and applications continue to be developed. Conclusions. This agent remains clinically important with the recent introduction of new commercially available products. Fibrin sealant has multiple new uses that should result in further improvements in patient care.

show abstract

Section: Fibrin Sealant Laboratory Literaturementioning

confidence: 99%

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

2014

View full text Add to dashboard Cite

show abstract

“…26,27 Previous studies have shown that fibrinogen concentration mainly determines the degradation of the fibrin gel part of the matrix and also affects the replacement with vascularized connective tissue. 28 We used a low, but well-studied, fibrinogen concentration of 10 mL/mg in this study to achieve a fast vascularization of the scaffolds. The polymerization time of the fibrin gel highly depends on the thrombin concentration.…”

mentioning

confidence: 99%

Evaluation of Angiogenesis of Bioactive Glass in the Arteriovenous Loop Model

Arkudas¹,

Balzer²,

Buehrer³

et al. 2013

Tissue Engineering Part C: Methods

Self Cite

View full text Add to dashboard Cite

In this study, the angiogenetic effect of sintered 45S5 Bioglass Ò was quantitatively assessed for the first time in the arteriovenous loop (AVL) model. An AVL was created by interposition of a venous graft from the contralateral side between the femoral artery and vein in the medial thigh of eight rats. The loop was placed in a Teflon isolation chamber and was embedded in a sintered 45S5 Bioglass Ò granula matrix filled with fibrin gel. Specimens were investigated 3 weeks postoperatively by means of microcomputed tomography, histological, and morphometrical techniques. All animals tolerated the operations well. At 3 weeks, both microcomputed tomography and histology demonstrated a dense network of newly formed vessels originating from the AVL. All constructs were filled with cell-rich, highly vascularized connective tissue around the vascular axis. Analysis of vessel diameter revealed constant small vessel diameters, indicating immature new vessel sprouts. This study shows for the first time axial vascularization of a sintered 45S5 Bioglass Ò granula matrix. After 3 weeks, the newly generated vascular network already interfused most parts of the scaffolds and showed signs of immaturity. The intrinsic type of vascularization allows transplantation of the entire construct using the AVL pedicle.

show abstract

“…In addition, it is absorbable and supports angiogenic ingrowth. 55,56 In this study, soaking the scaffolds with fibrin resulted in inferior results when compared with autologous serum and cell culture medium, possibly due to the special nanostructured architecture. Comparison of the two combination groups with expanded MSC and rhBMP-2 in fibrin and serum demonstrated that fibrin is not crucial for the delivery of the growth factor BMP-2 over time.…”

Section: New Bone Formation Depending On Implanted Cells and Carrier mentioning

confidence: 73%

Autologous serum improves bone formation in a primary stable silica-embedded nanohydroxyapatite bone substitute in combination with mesenchymal stem cells and rhBMP-2 in the sheep model

Boos

Weigand

Deschler

et al. 2014

IJN

Self Cite

View full text Add to dashboard Cite

New therapeutic strategies are required for critical size bone defects, because the gold standard of transplanting autologous bone from an unharmed area of the body often leads to several severe side effects and disadvantages for the patient. For years, tissue engineering approaches have been seeking a stable, axially vascularized transplantable bone replacement suitable for transplantation into the recipient bed with pre-existing insufficient conditions. For this reason, the arteriovenous loop model was developed and various bone substitutes have been vascularized. However, it has not been possible thus far to engineer a primary stable and axially vascularized transplantable bone substitute. For that purpose, a primary stable silica-embedded nanohydroxyapatite (HA) bone substitute in combination with blood, bone marrow, expanded, or directly retransplanted mesenchymal stem cells, recombinant human bone morphogenetic protein 2 (rhBMP-2), and different carrier materials (fibrin, cell culture medium, autologous serum) was tested subcutaneously for 4 or 12 weeks in the sheep model. Autologous serum lead to an early matrix change during degradation of the bone substitute and formation of new bone tissue. The best results were achieved in the group combining mesenchymal stem cells expanded with 60 μg/mL rhBMP-2 in autologous serum. Better ingrowth of fibrovascular tissue could be detected in the autologous serum group compared with the control (fibrin). Osteoclastic activity indicating an active bone remodeling process was observed after 4 weeks, particularly in the group with autologous serum and after 12 weeks in every experimental group. This study clearly demonstrates the positive effects of autologous serum in combination with mesenchymal stem cells and rhBMP-2 on bone formation in a primary stable silica-embedded nano-HA bone grafting material in the sheep model. In further experiments, the results will be transferred to the sheep arteriovenous loop model in order to engineer an axially vascularized primary stable bone replacement in clinically relevant size for free transplantation.

show abstract

Composition of fibrin glues significantly influences axial vascularization and degradation in isolation chamber model

Cited by 17 publications

References 34 publications

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

Fibrin Sealant: The Only Approved Hemostat, Sealant, and Adhesive—a Laboratory and Clinical Perspective

Evaluation of Angiogenesis of Bioactive Glass in the Arteriovenous Loop Model

Autologous serum improves bone formation in a primary stable silica-embedded nanohydroxyapatite bone substitute in combination with mesenchymal stem cells and rhBMP-2 in the sheep model

Contact Info

Product

Resources

About